Study of new drug for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of head and neck cancer called HNSCC, and it must have spread or come back and can't be fully removed by surgery or radiation.
- Your cancer must be in the mouth, throat (oropharynx, p16 positive or negative), voice box, or lower throat. It cannot be in the nasopharynx or sinuses.
- You need to be 18 or older, be able to do most daily activities (ECOG 0 or 1), and have a life expectancy of more than 12 weeks.
- You must be willing to have two new biopsies of your tumor during the study.
- You need to have adequate organ function (like kidneys and liver) and no active hepatitis B, C, or HIV.
- You cannot have had a prior treatment with certain B7-H3 targeted drugs, or have an autoimmune disease that required treatment in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a combination of three medicines (SYS6002, JMT101, and Enlonstobart) for people with head and neck cancer that has come back or spread and cannot be removed by surgery or radiation. The goal is to see if this treatment helps shrink tumors or slow the disease.
Hear when a new Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.